WHO recommendations for influenza virus vaccine composition for the 2018 southern hemisphere influenza season
The World Health Organization (WHO) has recommended the composition of the trivalent influenza vaccine for the southern hemisphere winter 2018 influenza season in a report published 28 September 2017.
Low uptake of seasonal influenza vaccination in Europe may jeopardise capacity to protect people in next pandemic
Influenza vaccination coverage among high-risk groups has dropped in the European Region over the last seven years, and half the countries report a decrease in the number of vaccine doses available.
WHO recommendations for influenza virus vaccine composition for the 2018-2019 Northern hemisphere season
On 19-21 February 2018 the World Health Organization (WHO) agreed on the recommended composition of the trivalent influenza vaccine for the northern hemisphere 2018-2019 influenza season.
Influenza vaccination coverage rates insufficient across EU Member States
None of the European Union (EU) Member States could demonstrate that they reach the EU target of 75% influenza vaccination coverage for vulnerable groups, according to a new report from the European Centre for Disease Prevention and Control (ECDC).
WHO recommendations for influenza virus vaccine composition for the 2019–2020 northern hemisphere season
On 18–20 February 2019, the World Health Organization (WHO) agreed on the recommended composition of the quadrivalent influenza vaccine for the northern hemisphere 2019–2020 influenza season: an A/Brisbane/02/2018 (H1N1)pdm09-like virus, an A(H3N2) virus component to be announced on 21 March 2019, a B/Colorado/06/2017-like virus (B/Victoria/2/87 lineage) and a B/Phuket/3073/2013-like virus (B/Yamagata/16/88 lineage).
World Health Organization recommendations for the influenza virus vaccine composition for the 2020 southern hemisphere season
On September 2019, WHO has agreed on the recommended composition of the quadrivalent and trivalent influenza vaccines for the southern hemisphere 2020 influenza season.
Looking at newer enhanced seasonal influenza vaccines: a systematic review of efficacy, effectiveness and safety
Based on a systematic literature review, ECDC assessed the efficacy, effectiveness and safety of newer and enhanced inactivated seasonal influenza (flu) vaccines among those 18 years or older. These assessed are MF59® adjuvanted, cell-based, high-dose, and recombinant haemagglutinin influenza vaccines.
The United States Advisory Committee on Immunization Practices votes for near universal recommendation for seasonal influenza vaccinationArchived
The United States Advisory Committee on Immunization Practices (ACIP), which advises the Centers for Disease Control and Prevention (CDC) on vaccine issues, voted to approve a new recommendation on February 24 to offer seasonal influenza vaccination to the whole population aged 6 months and older.
Influenza season 2010/11 – Norway’s risk assessment and revisited vaccine recommendationsArchived
An important conclusion from this process is that the current situation, with B viruses dominating (80%), is likely to continue through the season.
ECDC – VAESCO investigation into narcolepsyArchived
This initiative was taken following the indication of a potential association between the 2009 pandemic influenza A(H1N1) monvalent vaccine and the occurrence of narcolepsy following reports, especially in children from Finland and Sweden.